Welcome to our dedicated page for Amphastar Pharmaceuticals news (Ticker: AMPH), a resource for investors and traders seeking the latest updates and insights on Amphastar Pharmaceuticals stock.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Established in 1996, Amphastar is known for developing, manufacturing, and marketing injectable and inhalation products using state-of-the-art, cGMP-compliant facilities. The company operates five manufacturing facilities across the United States, China, and Europe, along with a cutting-edge new drug research center.
Amphastar's core business revolves around producing approximately 15 injectable products, with a strong focus on both generic and branded drugs that target large markets with high technical barriers to entry. The company's comprehensive portfolio includes injectable, inhalation, and intranasal products, catering to hospitals and urgent care clinical settings. These products are distributed through group purchasing organizations and drug wholesalers, with the majority of revenue being generated in the United States.
The company leverages its longstanding relationships with major group purchasing organizations and drug wholesalers in the U.S. to establish significant market share quickly. Amphastar's finished pharmaceutical products and Active Pharmaceutical Ingredient (API) products are divided into two main segments: Finished Pharmaceutical Products and API Products.
Recent achievements for Amphastar include the acquisition of commercially successful products like BAQSIMI® and the strategic expansion of their diabetes portfolio. The company reported impressive financial results for the third quarter of 2023, with net revenues of $180.6 million and a GAAP net income of $49.2 million. The strong performance was driven by their diabetes portfolio and the newly acquired BAQSIMI®.
Amphastar's product development pipeline is robust, with multiple ANDAs and biosimilar products targeting significant market opportunities. The company also announced the FDA approval of Albuterol Sulfate Inhalation Aerosol, marking a milestone in their ability to develop complex generic inhalation products. This approval reflects Amphastar’s technological and manufacturing expertise, positioning the company for future growth.
Amphastar's commitment to quality and innovation is further demonstrated by their strategic acquisition and integration activities, focused on maximizing commercial potential and delivering high-quality pharmaceutical solutions. The company continues to enhance its pipeline with both generic and proprietary products, targeting products with large market sizes and high growth potential.
For more information, visit www.amphastar.com.
Eli Lilly (NYSE: LLY) has announced a definitive agreement to sell its glucagon product BAQSIMI to Amphastar Pharmaceuticals (NASDAQ: AMPH) for $500 million at closing and an additional $125 million after one year. This divestiture aims to enhance the accessibility of BAQSIMI, the first nasal glucagon treatment for severe hypoglycemia in diabetes patients. BAQSIMI generated worldwide sales of $139.3 million in 2022, and the deal is expected to close in Q2 or Q3 2023. Both companies' boards have approved the agreement, which includes potential sales-based milestone payments of up to $450 million. Amphastar plans to invest in BAQSIMI to improve treatment access for those on insulin, aligning with its strategic focus on expanding its diabetes portfolio.
Amphastar Pharmaceuticals (NASDAQ:AMPH) announced a business update and a conference call scheduled for April 24, 2023, at 6:00 AM Pacific Time. Interested parties can join the call by calling 877-407-0989 or +1 201-389-0921 for international access. The live call will be available on the Amphastar Investors page, with a replay accessible post-event.
Amphastar focuses on developing, manufacturing, and selling generic and proprietary injectable, inhalation, and intranasal products, primarily for clinical settings. The company also sells insulin API products. The press release includes forward-looking statements regarding financial performance, product development timelines, and market conditions, emphasizing the potential impact of external factors like COVID-19 and geopolitical events on its operations.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced its participation in the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 12:45 PM Eastern Time. Key executives, including Bill Peters (CFO) and Jacob Liawatidewi (EVP of Corporate Administration), will engage in an Analyst-Moderated fireside chat. The event can be accessed via Amphastar’s website, where a recording will be available for 90 days post-presentation.
Amphastar specializes in developing and marketing generic and proprietary injectables, inhalation, and intranasal products, primarily used in clinical settings. The company also sells insulin active pharmaceutical ingredients. For further details, visit their website.
This announcement includes forward-looking statements regarding Amphastar's expectations for future business performance and market conditions.
Amphastar Pharmaceuticals (NASDAQ:AMPH) announced FDA approval for its naloxone hydrochloride nasal spray 4mg, aimed at treating opioid overdoses in both adults and children. This innovation is expected to alleviate the opioid crisis by improving access to critical treatment. In 2022, U.S. sales for naloxone nasal spray reached approximately $250 million. Amphastar's pipeline includes three ANDAs, three biosimilars, and six generics targeting markets exceeding $23 billion. The company has also filed 17 Drug Master Files, with multiple proprietary products in development, enhancing its position in the competitive pharmaceutical landscape.
Amphastar Pharmaceuticals reported strong fourth-quarter results for the period ending December 31, 2022, showcasing net revenues of $135.0 million, a 12% increase from the previous year. The company achieved a GAAP net income of $33.9 million, or $0.66 per share. For the full fiscal year, net revenues reached $499.0 million, up 14%, with GAAP net income totaling $91.4 million, or $1.74 per share. The growth was driven by increased sales of key products like epinephrine and Primatene MIST. Looking ahead, Amphastar plans to launch multiple new products to sustain growth.
Amphastar Pharmaceuticals (NASDAQ:AMPH) is set to announce its fourth-quarter earnings for 2022 on February 28, 2023, after market closure. A conference call will follow at 2:00 p.m. PT to discuss the financial results. Interested parties can join by dialing (877) 407-0989 or (201) 389-0921 for international calls. Amphastar specializes in developing and selling generic and proprietary injectable, inhalation, and intranasal products, focusing on hospital use. The company emphasizes that its future performance statements are forward-looking and subject to various uncertainties, including COVID-19 impacts and macroeconomic conditions.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will have Bill Peters, CFO, and Tony Marrs, Sr. VP of Regulatory Affairs, participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 11:00 AM ET. Access the webcast via Amphastar's website, available for 90 days post-event. Amphastar focuses on developing and selling challenging generic and proprietary products, mainly targeting hospital use. More info can be found at www.amphastar.com.
Amphastar Pharmaceuticals (NASDAQ:AMPH) announces participation in the Analyst-Moderated fireside chat at the 2022 Jefferies London Healthcare Conference on November 16, 2022, at 3:50 PM GMT. Bill Peters, CFO, and Jacob Liawatidewi, Executive V.P., will represent the company. The presentation will be accessible on Amphastar's website for 90 days. Amphastar specializes in developing and selling generic and proprietary injectable and inhalation products, predominantly used in clinical settings.
FAQ
What is the current stock price of Amphastar Pharmaceuticals (AMPH)?
What is the market cap of Amphastar Pharmaceuticals (AMPH)?
What does Amphastar Pharmaceuticals, Inc. specialize in?
Where are Amphastar’s manufacturing facilities located?
What are Amphastar’s main product segments?
What recent product approval has Amphastar received from the FDA?
How does Amphastar distribute its products?
What significant acquisition has Amphastar completed recently?
What are the financial highlights for Amphastar’s third quarter of 2023?
What is the focus of Amphastar’s product development pipeline?
Where can I find more information about Amphastar Pharmaceuticals?
What are some key products in Amphastar’s portfolio?
